Literature DB >> 30121804

Pragmatic criteria to define chronic pseudomonas aeruginosa infection among adults with cystic fibrosis.

Zhe Hui Hoo1,2, Elizabeth Coates3, Chin Maguire3, Hannah Cantrill3, Nadia Shafi4, Edward F Nash5, Angela McGowan6, Stephen J Bourke7, William G Flight8, Thomas V Daniels9, Julia A Nightingale9, Mark I Allenby9, Rachael Curley3,10, Martin J Wildman3,10.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30121804     DOI： 10.1007/s10096-018-3358-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  17 in total

Review 1.  Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.

Authors:  Peter J Mogayzel; Edward T Naureckas; Karen A Robinson; Gary Mueller; Denis Hadjiliadis; Jeffrey B Hoag; Lisa Lubsch; Leslie Hazle; Kathy Sabadosa; Bruce Marshall
Journal:  Am J Respir Crit Care Med       Date:  2013-04-01       Impact factor: 21.405

2.  Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre.

Authors:  M Proesmans; W Balinska-Miskiewicz; L Dupont; X Bossuyt; J Verhaegen; N Høiby; K de Boeck
Journal:  Eur Respir J       Date:  2006-05       Impact factor: 16.671

Review 3.  Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection.

Authors:  Peter J Mogayzel; Edward T Naureckas; Karen A Robinson; Cynthia Brady; Margaret Guill; Thomas Lahiri; Lisa Lubsch; Jane Matsui; Christopher M Oermann; Felix Ratjen; Margaret Rosenfeld; Richard H Simon; Leslie Hazle; Kathy Sabadosa; Bruce C Marshall
Journal:  Ann Am Thorac Soc       Date:  2014-12

4.  Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.

Authors:  Elizabeth L Salsgiver; Aliza K Fink; Emily A Knapp; John J LiPuma; Kenneth N Olivier; Bruce C Marshall; Lisa Saiman
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

5.  How and why to monitor Pseudomonas aeruginosa infections in the long term at a cystic fibrosis centre.

Authors:  L Kalferstova; K Vilimovska Dedeckova; M Antuskova; O Melter; P Drevinek
Journal:  J Hosp Infect       Date:  2015-10-08       Impact factor: 3.926

6.  The combination of PCR and serology increases the diagnosis of Pseudomonas aeruginosa colonization/infection in cystic fibrosis.

Authors:  Luiz Vicente F da Silva Filho; Adriana F Tateno; Kátia M Martins; Ana Carolina Azzuz Chernishev; Doroti de Oliveira Garcia; Maria Haug; Christoph Meisner; Joaquim C Rodrigues; Gerd Döring
Journal:  Pediatr Pulmonol       Date:  2007-10

7.  Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

Authors:  Tim W R Lee; Keith G Brownlee; Steven P Conway; Miles Denton; James M Littlewood
Journal:  J Cyst Fibros       Date:  2003-03       Impact factor: 5.482

8.  Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.

Authors:  Baroukh M Assael; Tacjana Pressler; Diana Bilton; Michael Fayon; Rainald Fischer; Raphael Chiron; Mario LaRosa; Christiane Knoop; Noel McElvaney; Sandra A Lewis; Mark Bresnik; A Bruce Montgomery; Christopher M Oermann
Journal:  J Cyst Fibros       Date:  2012-09-15       Impact factor: 5.482

9.  Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis.

Authors:  Henry L Dorkin; Doris Staab; Elisabeth Operschall; Jeff Alder; Margarita Criollo
Journal:  BMJ Open Respir Res       Date:  2015-12-02

10.  Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision.

Authors:  Zhe Hui Hoo; Frank Peter Edenborough; Rachael Curley; Laura Prtak; Jane Dewar; Mark Ivan Allenby; Julia Anne Nightingale; Martin James Wildman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-06       Impact factor: 3.267
View more
  1 in total

1.  The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis.

Authors:  Mohamed Al-Aloul; Dilip Nazareth; Martin Walshaw
Journal:  Clin Kidney J       Date:  2019-02-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.